Generic Veozah Availability
Last updated on Oct 9, 2024.
Veozah is a brand name of fezolinetant, approved by the FDA in the following formulation(s):
VEOZAH (fezolinetant - tablet;oral)
Has a generic version of Veozah been approved?
No. There is currently no therapeutically equivalent version of Veozah available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Veozah. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists
Patent 10,836,768
Issued: November 17, 2020
Inventor(s): Hoveyda Hamid & Dutheuil Guillaume & Fraser Graeme
Assignee(s): Ogeda SAA method for treating and/or preventing polycystic ovary syndrome (PCOS) including the administration, to a patient in need thereof, of a pharmaceutically effective amount of a compound of Formula I
Patent expiration dates:
- March 28, 2034✓
- March 28, 2034
-
NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders
Patent 8,871,761
Issued: October 28, 2014
Inventor(s): Hoveyda Hamid R. & Roy Marie-Odile & Fraser Graeme Lovat & Dutheuil Guillaume
Assignee(s): Euroscreen S.A.The present invention is directed to novel compounds of formula I
Patent expiration dates:
- April 4, 2031✓
- April 4, 2031
-
Substituted [1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists
Patent 9,422,299
Issued: August 23, 2016
Inventor(s): Hoveyda Hamid & Dutheuil Guillaume & Fraser Graeme
Assignee(s): EUROSCREEN SANovel compounds of Formula I
Patent expiration dates:
- March 28, 2034✓✓✓
- March 28, 2034
-
N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists
Patent 9,987,274
Issued: June 5, 2018
Inventor(s): Hoveyda Hamid & Dutheuil Guillaume & Fraser Graeme
Assignee(s): OGEDA SAA method for treating and/or preventing hot flashes, by administering, to a patient in need thereof, of a pharmaceutically effective amount of a compound of Formula I
Patent expiration dates:
- March 28, 2034✓
- March 28, 2034
Related exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
Exclusivity expiration dates:
- May 12, 2028 - NEW CHEMICAL ENTITY
More about Veozah (fezolinetant)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (23)
- Drug images
- Latest FDA alerts (1)
- Side effects
- Dosage information
- Patient tips
- During pregnancy
- FDA approval history
- Drug class: miscellaneous central nervous system agents
- En español
Patient resources
Professional resources
Related treatment guides
Glossary
Term | Definition |
---|---|
Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.